120 related articles for article (PubMed ID: 38253116)
1. The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT
Arias HR; Rudin D; Hines DJ; Contreras A; Gulsevin A; Manetti D; Anouar Y; De Deurwaerdere P; Meiler J; Romanelli MN; Liechti ME; Chagraoui A
Eur J Pharmacol; 2024 Mar; 966():176329. PubMed ID: 38253116
[TBL] [Abstract][Full Text] [Related]
2. DM506 (3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-
Tae HS; Ortells MO; Tekarli BJ; Manetti D; Romanelli MN; McIntosh JM; Adams DJ; Arias HR
ACS Chem Neurosci; 2023 Jul; 14(14):2537-2547. PubMed ID: 37386821
[TBL] [Abstract][Full Text] [Related]
3. Coronaridine congeners induce sedative and anxiolytic-like activity in naïve and stressed/anxious mice by allosteric mechanisms involving increased GABA
Arias HR; De Deurwaerdère P; Scholze P; Sakamoto S; Hamachi I; Di Giovanni G; Chagraoui A
Eur J Pharmacol; 2023 Aug; 953():175854. PubMed ID: 37331683
[TBL] [Abstract][Full Text] [Related]
4. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.
Fantegrossi WE; Simoneau J; Cohen MS; Zimmerman SM; Henson CM; Rice KC; Woods JH
J Pharmacol Exp Ther; 2010 Dec; 335(3):728-34. PubMed ID: 20858706
[TBL] [Abstract][Full Text] [Related]
5. Non-hallucinogenic compounds derived from iboga alkaloids alleviate neuropathic and visceral pain in mice through a mechanism involving 5-HT
Arias HR; Micheli L; Rudin D; Bento O; Borsdorf S; Ciampi C; Marin P; Ponimaskin E; Manetti D; Romanelli MN; Ghelardini C; Liechti ME; Di Cesare Mannelli L
Biomed Pharmacother; 2024 Jun; 177():116867. PubMed ID: 38889634
[TBL] [Abstract][Full Text] [Related]
6. Effects of the 5-HT
Jaster AM; Elder H; Marsh SA; de la Fuente Revenga M; Negus SS; González-Maeso J
Psychopharmacology (Berl); 2022 Jun; 239(6):1665-1677. PubMed ID: 35233648
[TBL] [Abstract][Full Text] [Related]
7. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors.
Delgado M; Caicoya AG; Greciano V; Benhamú B; López-Rodríguez ML; Fernández-Alfonso MS; Pozo MA; Manzanares J; Fuentes JA
Eur J Pharmacol; 2005 Mar; 511(1):9-19. PubMed ID: 15777774
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Mechanism of the Non-hallucinogenic 5-HT
Cunningham MJ; Bock HA; Serrano IC; Bechand B; Vidyadhara DJ; Bonniwell EM; Lankri D; Duggan P; Nazarova AL; Cao AB; Calkins MM; Khirsariya P; Hwu C; Katritch V; Chandra SS; McCorvy JD; Sames D
ACS Chem Neurosci; 2023 Jan; 14(1):119-135. PubMed ID: 36521179
[TBL] [Abstract][Full Text] [Related]
9. The adrenergic receptor antagonist carvedilol interacts with serotonin 2A receptors both in vitro and in vivo.
Murnane KS; Guner OF; Bowen JP; Rambacher KM; Moniri NH; Murphy TJ; Daphney CM; Oppong-Damoah A; Rice KC
Pharmacol Biochem Behav; 2019 Jun; 181():37-45. PubMed ID: 30998954
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice.
Nic Dhonnchadha BA; Hascoët M; Jolliet P; Bourin M
Behav Brain Res; 2003 Dec; 147(1-2):175-84. PubMed ID: 14659583
[TBL] [Abstract][Full Text] [Related]
11. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.
Halberstadt AL; van der Zee JVF; Chatha M; Geyer MA; Powell SB
Psychopharmacology (Berl); 2019 Feb; 236(2):821-830. PubMed ID: 30448990
[TBL] [Abstract][Full Text] [Related]
13. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.
Fantegrossi WE; Gray BW; Bailey JM; Smith DA; Hansen M; Kristensen JL
Psychopharmacology (Berl); 2015 Mar; 232(6):1039-47. PubMed ID: 25224567
[TBL] [Abstract][Full Text] [Related]
14. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
Marek GJ; Aghajanian GK
J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
[TBL] [Abstract][Full Text] [Related]
15. ALEPH-2, a suspected anxiolytic and putative hallucinogenic phenylisopropylamine derivative, is a 5-HT2a and 5-HT2c receptor agonist.
Acuña-Castillo C; Scorza C; Reyes-Parada M; Cassels BK; Huidobro-Toro JP
Life Sci; 2000 Nov; 67(26):3241-7. PubMed ID: 11191631
[TBL] [Abstract][Full Text] [Related]
16. RP 59037 and RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential. interaction with the gamma-aminobutyric acidA/benzodiazepine receptor complex and behavioral effects in the rodent.
Doble A; Canton T; Dreisler S; Piot O; Boireau A; Stutzmann JM; Bardone MC; Rataud J; Roux M; Roussel G
J Pharmacol Exp Ther; 1993 Sep; 266(3):1213-26. PubMed ID: 8103792
[TBL] [Abstract][Full Text] [Related]
17. Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test.
Nic Dhonnchadha BA; Ripoll N; Clénet F; Hascoët M; Bourin M
Psychopharmacology (Berl); 2005 May; 179(2):418-29. PubMed ID: 15821956
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action.
Bourin M; Masse F; Dailly E; Hascoët M
Pharmacol Biochem Behav; 2005 Jul; 81(3):645-56. PubMed ID: 15961146
[TBL] [Abstract][Full Text] [Related]
19. Differences across sexes on head-twitch behavior and 5-HT
Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J
Neurosci Lett; 2022 Sep; 788():136836. PubMed ID: 35963476
[TBL] [Abstract][Full Text] [Related]
20. New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.
Jurczyk S; Kołaczkowski M; Maryniak E; Zajdel P; Pawłowski M; Tatarczyńska E; Kłodzińska A; Chojnacka-Wójcik E; Bojarski AJ; Charakchieva-Minol S; Duszyńska B; Nowak G; Maciag D
J Med Chem; 2004 May; 47(10):2659-66. PubMed ID: 15115407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
